k8凯发(中国)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF TQB3142 “BcL-xL PROTAC”ACCEPTED BY NMPA

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF TQB3122 "PARP1 INHIBITOR" ACCEPTED BY NMPA

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR PHASE II CLINICAL TRIAL ON LM-24C5 "CEACAM5/4-1BB BISPECIFIC ANTIBODY" APPROVED BY THE NMPA

VOLUNTARY ANNOUNCEMENT - ROVADICITINIB TABLET "JAK/ROCK INHIBITOR" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINCAL TRIAL OF TQC3302 "ICS/LAMA/LABA SOFT MIST INHALATION FORMULATION" APPROVED BY NMPA

NOTIFICATION OF BOARD MEETING

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025